image: Octapharma USA presented research at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting evaluating the efficacy and safety of cutaquig® (Immune Globulin Subcutaneous ...

According to FDA, the syringe pumps can cause "serious clinical consequences from lack of flow continuity resulting in delay of therapy, over-infusion or under-infusion," when operating at a rate of ...

PARAMUS, N.J. (May 18, 2023) – An Octapharma-sponsored study published recently in The Journal of Clinical Immunology concludes that cutaquig ® (Immune Globulin Subcutaneous [Human]-hipp, 16.5% ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency ...

Longitudinal study of anti-myeloma treatment patterns in a U.S. commercial population before and after approval of bortezomib (BOR). The utility and prognostic value of positron emission tomography ...

Infusion centers are caught between two forces that won’t relent: patient volumes that keep climbing and clinician pipelines that can’t keep pace. For many organizations, the instinct is to hire more ...

With its high patient volume and mission to deliver comprehensive cancer care “from bed to bench” for each patient, University of California San Diego’s (UCSD) Moores Cancer Center prioritizes its ...